Text this: EVALUATING THE CARDIOVASCULAR BENEFITS OF SGLT2 INHIBITORS IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY AND HEART FAILURE WITH PRESERVED EJECTION FRACTION